Cargando…
Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes
Hepatic sinusoidal obstruction syndrome (HSOS) can be caused by the intake of pyrrolizidine alkaloids (PAs). To date, PAs-induced HSOS has not been extensively studied. In view of the difference in etiology of HSOS between the West and China, clinical profiles, imaging findings, treatment, and outco...
Autores principales: | Yang, Xiao-Qian, Ye, Jin, Li, Xin, Li, Qian, Song, Yu-Hu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676551/ https://www.ncbi.nlm.nih.gov/pubmed/31391770 http://dx.doi.org/10.3748/wjg.v25.i28.3753 |
Ejemplares similares
-
Plateletcrit for predicting prognosis in patients with hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloid
por: Tu, Hongfei, et al.
Publicado: (2022) -
Diagnostic performance of Contrast-enhanced CT in Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstructive Syndrome
por: Kan, Xuefeng, et al.
Publicado: (2016) -
Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome
por: Zhang, Wei, et al.
Publicado: (2021) -
Transjugular intrahepatic portosystemic shunt for pyrrolizidine alkaloid-related hepatic sinusoidal obstruction syndrome
por: Zhou, Chun-Ze, et al.
Publicado: (2020) -
Prognostic risk factors for patients with hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids
por: Du, Xiaofei, et al.
Publicado: (2023)